Research & Reports

Corporate stories about Research & Reports across 3BL's network.

Latest in Research & Reports

Not Always Better: Big Company ESG
CSRHub's Bahar Gidwani's research on the correlation between a company's revenue in relation to ESG ratings and sources.
The Ray and NGI Release Their NextGen Highways Feasibility Study for the Minnesota Department of Transportation
The Ray and NGI Consulting have released a feasibility study for the Minnesota Dept. of Transportation showing the value of burying high-voltage direct current (HVDC) transmission systems in the highway right-of-way for cost-effective clean energy.
Climate Action - Ericsson Owns Their Carbon Emissions
In 2021, Ericsson expanded its carbon neutral target for own operations into the Net Zero emissions target for own activities by 2030.
Latest Research Finds Plan Access and Plan Design Significantly Impacts Retirement Savings
T. Rowe Price released new research based on its annual Retirement Savings and Spending survey and analysis of the Census Bureau’s 2021 Current Population Survey.
Four Ways Investors Can Act on Climate Change
As scientists warn about a shifting climate, more investors are thinking about environmental risks and how they might affect their portfolios.
Green Plains Achieves 35% Emissions Reduction, on Track for Carbon Neutrality by 2050
Green Plains Inc. (NASDAQ:GPRE) today released its 2021 Sustainability Report, outlining environmental, social and governance (ESG) priorities, progress and targets.
Investics to Provide CSRHub ESG Data
Investics announced an expansion of ESG data and analytics capabilities with the addition of CSRHub data to provide data and CSR analysis on their Investics Cloud Ecosystem platform.
How to Avoid Greenwashing When Choosing ESG Investments
This article includes some steps that you can take to perform effective ESG due diligence and avoid being misled by labels
In an Extraordinary Year, Vertex Continues Its Unwavering Commitment to Corporate Responsibility; Announces 2021 CR Report
2021 was an important year for Vertex and one that positioned the company well for the future as they continued to discover, develop and commercialize transformative medicines for people with serious diseases